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Abstract
The role of an innovative Pharmacist Independent Prescriber (PIP) for care homes to 
optimise medications has not been examined. We explored stakeholders’ views on 
issues and barriers that the PIP might address to inform a service specification for 
the PIP intervention in older people's care homes. Focus groups (n = 72 participants) 
and semi-structured interviews (n = 13) undertaken in 2015 across four sites in the 
United Kingdom captured the views of doctors, pharmacists, care-home managers 
and staff, residents and relatives. Stakeholders identified their expectations of what 
service should be provided by PIPs, what might affect their support for the role, and 
barriers and enablers to providing the service. Transcripts were analysed using the 
Theoretical Domains Framework to identify key components, which were reviewed 
by stakeholders in 2016. A PIP service was envisaged offering benefits for residents, 
care homes and doctors but stakeholders raised challenges including agreement on 
areas where PIPs might prescribe, contextual barriers in chronic disease management, 
PIPs’ knowledge of older people's medicine, and implementation barriers in integrated 
team-working and ensuring role clarity. Introducing a PIP was welcomed in principle 
but conditional on: a clearly defined PIP role communicated to stakeholders; collabo-
ration across doctors, PIPs and care-home staff; dialogue about developing the service 
with residents and relatives, based on trust and effective communication. To embed a 
PIP service within increasingly complex care-homes provision, the overarching theme 
from this research was that everyone must “understand each other's systems”.
K E Y W O R D S
care homes, medicines management, older people, pharmaceutical care, prescribing, 
qualitative research
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1  | INTRODUC TION
It has been demonstrated that medicines management in residen-
tial settings for older people (hereafter referred to as “care homes”) 
in the United Kingdom (UK), should be improved (Care Quality 
Commission, 2010; Furniss et al., 2000; Kirthisingha, 2014). Providing 
a designated individual with overall continuing responsibility for the 
medicines management of individual care-home residents might ad-
dress identified shortcomings in medicine-related care (Alldred et al., 
2009). Pharmacist-led medication reviews can achieve positive out-
comes, such as reduced prescribing of inappropriate medications 
and resolving medication-related problems (Alldred et al., 2009; 
Roberts et al., 2001; Zermansky et al., 2006). Furthermore, a model 
which relocates medication-related decisions involving pharmacists 
more firmly within the context of care homes could improve resi-
dent-related outcomes (Alldred, Kennedy, Hughes, Chen, & Miller, 
2016; Patterson et al., 2014). Guidelines from the UK’s National 
Institute for Health and Care Excellence (NICE) recommend a holis-
tic overview of medicines management (NICE, 2014), while a profes-
sional report proposes pharmacists having “overall responsibility for 
medicines and their use in care homes” and that a pharmacist and a 
family physician (in the UK called general practitioners [GPs]) share 
responsibility for medicines, “ensuring coordinated and consistently 
high standards of care” (Royal Pharmaceutical Society [RPS], 2016, p. 
2). UK legislation (Department of Health, 2006) permits pharmacists 
to qualify as independent prescribers, able to diagnose and prescribe 
medicines, enabling them to implement changes following medica-
tion review, rather than recommending changes to a medical pre-
scriber. Prescribing pharmacists may prescribe within their area of 
competence. For our study, the area of competence is “frail elderly 
residing in care homes”.
This paper reports an early-stage qualitative study which ex-
plored stakeholders’ expectations and understandings of introduc-
ing a new service. This was part of the Care Homes Independent 
Pharmacist Prescribing Study (CHIPPS), a 5-year, National Institute 
for Health Research-funded research programme which is devel-
oping and evaluating the effectiveness and cost-effectiveness of a 
novel Pharmacist Independent Prescriber (PIP) role to take overall 
clinical responsibility for managing repeat prescriptions in older 
people's care homes, aiming to optimise their medicines manage-
ment (ordering, storage, prescribing, monitoring, administration) 
for an enhanced quality of life. It is following the iterative process 
recommended by the Medical Research Council for the develop-
ment and evaluation of complex interventions, finishing with a de-
finitive trial (Medical Research Council, 2000). The qualitative study 
was designed to inform how this service should be introduced, to 
mitigate potential barriers and deliver an acceptable service. The 
research question asked what components stakeholders would 
specify in a PIP service they deemed feasible and acceptable and 
what they considered barriers and enablers to implementing such 
a service. Stakeholders were accessed in four study sites: England 
(two), Scotland and Northern Ireland (one in each), all differing in 
demographic and cultural make-up.
2  | METHODS
2.1 | Design
Qualitative methods drew on a phenomenological approach to en-
able us to explore less-known ideas and priorities of stakeholders 
in the context of their experiences of care-homes’ work organisa-
tion. Our approach drew on the Theoretical Domains Framework 
(TDF; Cane, O’Connor, & Michie, 2012) to systematise our search 
for contextual practices which stakeholders might judge as relevant 
to their actions within organisations and potentially affected by a 
PIP initiative. Framework analysis of the data was informed by the 
TDF, and was used to identify key components for a potential ser-
vice specification and barriers and facilitators to changes in clini-
cal practice which might accommodate a PIP service in care homes 
(Kirk, Sivertesen, Petersen, Nilsen, & Petersen, 2016; McGoldrick, 
Crawford, Brown, Groom, & Crowther, 2016).
2.2 | Sampling
A purposive sampling approach to secure views of stakeholders with 
experience of living or working in or with care homes was taken to 
maximise the range of relevance of data collected to the research 
goals (Bryman, 2012). Stakeholders were GPs, pharmacists, care-
home managers, care-home staff, care-home residents and resi-
dents’ relatives, spanning urban and rural areas, single and multi-GP 
What is known about this topic
• Medication errors are common in care-home 
environments.
• The current approach of pharmacists external to care-
home settings reviewing older residents’ medicines has 
demonstrated better medicines management but not 
improvement in clinical outcomes.
• To improve residents’ medicine-related care, research-
ers recommend one person should take central respon-
sibility for medicines management.
What this paper adds
• A prescribing pharmacist taking this central role is 
widely perceived as likely to reduce medication errors 
and improve residents’ medicine-related care.
• For this innovation to work, everyone in care homes 
must understand each other's roles.
• Integrated team-working, knowledge of older people's 
health and effective communication with residents and 
relatives were identified as essential to make the pre-
scribing pharmacist role acceptable.
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practices and chain and family-run care homes. GPs were contacted 
through research team and local professional networks. Pharmacists 
in primary care (linked to GP practices and providing care to care 
homes) were approached through health services organisations, 
while community pharmacists were contacted through local profes-
sional networks. Care homes were contacted through the national 
Care Quality Commission website and site-specific regulatory bod-
ies, local primary care and care-home networks. A maximally varying 
sample was observed: care homes with or without nursing manag-
ers; with residents living with dementia; with both nursing and care 
residents and with diverse funding arrangements (local-authority, 
private, mixed). Local network partners in each site emailed letters 
of invitation to each stakeholder group; this included a Participant 
Information Sheet and Expression of Interest Form. The latter in-
vited interest to participate in a stakeholder-specific focus group of 
up to eight participants. Potential participants were informed that, 
if unavailable for the focus group, they could ask to take part in an 
individual interview. Table 1 summarises participant numbers and 
types in each group.
2.3 | Data collection
Ethical approval was obtained from the NHS National Research 
Ethics Service on 10 April 2015 (REC reference, 15/YH/0172). A 
semi-structured topic guide informed by the TDF for Behaviour 
Change was used to develop questions linked to constituent domains 
so as to identify expected characteristics, barriers and benefits of 
the proposed PIP role (Table 2). These included topics relating to 
knowledge, skills, environment, beliefs about consequences, prac-
tice features in the pharmacy context, older people in residential 
settings and primary-care practice. We drew on the interdisciplinary 
research team's broad experience to identify both theory- and 
practice-related data-collection topics with context-relevance. For 
example, questions exploring current medicines management aimed 
to tap stakeholders’ knowledge of scientific, procedural or environ-
mental factors shaping care-home practices, how a PIP service might 
work, and its potential benefits and risks. Questions eliciting stake-
holder views on how the GP-PIP partnership would work focused 
explicitly on social and professional roles and identity. Training-
related questions, while included on the topic guide, are reported in 
a separate paper.
Consent forms were distributed at each focus group and inter-
view, where researchers also outlined their purpose and process. 
Information sheets were also available at each episode of data-col-
lection to help participants refresh their familiarity with the study. 
Focus groups for residents and relatives included the option for res-
idents to have a carer for support (with two focus groups including 
carers supporting residents). We took care to communicate clearly 
with residents, respecting any needs for time to consider the pro-
cess or answer questions; we reassured them that, as with all study 
participants, they were free not to respond or to leave the focus 
group, without giving a reason. Participants having telephone or 
Skype© interviews received a consent form electronically, returning 
it to the research team prior to interview. All participants were given 
the opportunity to ask questions. Before commencing data-col-
lection, researchers double-checked that participants understood 
that the discussion would be audio-recorded. Focus groups lasted 
60–90 min for GPs and pharmacists and 60 min for others, except 
TA B L E  1   Numbers of participants per stakeholder group
Stakeholder group 
(abbrev.) and study 
sites involveda 
Focus group 
(number of 
groups) Interview
Total 
participants
Pharmacists (P)—all  
4 UK sites
25 (4) 2 27
GPs (GP)—all 4 UK 
sites
24 (4) 5 29
Care-home managers 
(CHM)—all 4 UK 
sites
3 (1) 3 6
Care-home staff 
(CHS)—England 
(2) and Northern 
Ireland
6 (2) 3 9
Residents and 
Relatives (RR)—
England and 
Scotland
7 Residents
7 Relatives
= 14 (2)
0 14
Total 72 13 85
aThe four UK study sites: England (two), Scotland, Northern Ireland. 
TA B L E  2   Topic guide for focus groups and interviews linked 
with domains in the theoretical domains framework
TDF domains (where 
applicable) Question
 What is your role?
Knowledge
Professional role
Skills
Environmental context
How are medicines managed at the 
moment in your experience for 
care-home residents?
Knowledge
Beliefs about capabilities
Beliefs about consequences
Skills
What might be the key ingredients 
of a PIP service?
Beliefs about capabilities
Environmental context and 
resources
What organisational barriers could 
affect putting this into practice?
Social professional role and 
identity
Social influences
What professional barriers could 
affect putting this into practice?
Intention
Goals
What might be the solutions to 
these barriers?
Skills
Behavioural regulation
What could we include in training 
pharmacists undertaking this role?
 Is there anything else important 
about this proposed service you 
want to mention?
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for one residents’ and relatives’ group (32 min) and one with care-
home staff (21 min). Two researchers facilitated each focus group, 
one leading and the second note-taking. Interviews, conducted by 
one researcher, lasted 25–35 min; three face-to-face and ten tele-
phone or Skype©.
2.4 | Analysis
All interviews were transcribed verbatim. Participants’ identities 
were anonymised and personally identifying references removed. 
Analysis began with repeated reading of the transcripts, to identify 
initial codes and themes from the data, then using the TDF-informed 
questions (Table 2) to set up the framework analysis we had planned 
to use to identify key components relevant to our study design. 
Consensus about identified and emergent codes, themes and sub-
themes and their relationships was reached by two qualitative re-
searchers engaging in an iterative process, supported by rigorous 
re-reading of data. After the first round of analysis, an intervention-
development workshop was held at each site with invited local 
participants from mixed stakeholder groupings. The mixed-group 
participants were presented with themes and topics from focus 
group and interview findings, as a stimulus from which they identi-
fied their specific issues with shortcomings and benefits in managing 
medicines in care homes and in light of what PIP-related changes 
they foresaw. All of these were variously endorsed and elaborated 
in the stakeholder focus groups and interviews reported in the fol-
lowing findings.
3  | FINDINGS
Thirteen stakeholder group-specific focus groups (n = 72 partici-
pants) and 13 interviews (n = 13 participants) were held with GPs, 
pharmacists, pharmacy technician, care-home managers, care-home 
staff, residents and residents’ relatives in four study sites (Table 1). 
Of 27 pharmacy professional participants, 15 pharmacists worked 
in primary care, 10 in the community and one in both sectors; one 
pharmacy technician worked in the community (Table 3).
All focus group, interview and workshop stakeholders wel-
comed introducing a PIP into care homes in principle. Their rea-
sons included viewing this new role as relevant for improving 
medicines management, benefiting residents, overcoming com-
munication lapses between care home, GP practice and pharmacy, 
and providing medicines-relevant communication between the GP, 
residents and their relatives. Nonetheless, stakeholders identified 
specific potential contextual and implementation barriers and fa-
cilitators for introducing an acceptable and viable PIP service in 
older people's care homes. Stakeholders strongly agreed that all 
parties must “understand each other's systems”, specifically in re-
lation to:
• chronic disease management (contextual)
• knowledge of older people's medicine and care homes (contextual)
• clarity of a PIP’s role and responsibilities (implementation)
• integrated social and professional team-working (implementation).
These are reflected in the organisation of findings now pre-
sented here.
3.1 | Contextual barriers and facilitators
Chronic disease management and knowledge of older people's 
medicine and of care homes were seen to underpin an effective PIP 
service. Where lacking, these constituted contextual barriers. The 
barriers encompassed current knowledge and understanding, the 
potential need to reframe aspects of these, key organisations and 
stakeholder groups involved, cultural practices within care homes, 
governance and policies.
3.1.1 | Chronic disease management
All stakeholders emphatically identified chronic disease manage-
ment as a core issue in managing medicines in care homes, em-
phasising monitoring and reviewing concerns. They considered a 
viable PIP service would depend on successfully addressing the 
“many points in the circuit of prescribing where it can go wrong” 
(GP15-FG).1  They also highlighted a number of challenges to ensur-
ing effective chronic disease management, such as working patterns 
which disrupted continuity of residents’ care, infrequent medica-
tion reviews, communication shortcomings in ordering medications, 
and minimal proactive oversight of medications within care homes.
GPs’ working patterns, together with the many care-home staff 
involved with medicines, were seen to constrain effective chronic 
disease management and how residents’ medication needs were 
communicated. As a GP noted:
…one doctor’s introducing a new medication maybe for 
a short period … then the [care home] phone up and 
ask another doctor, ‘are we supposed to continue this?’. 
That’s maybe communication failures on our part but 
there’s more and more people becoming involved with 
each patient and …that can cause problems (GP5-I)
TA B L E  3   Characteristics of pharmacy professional participants
Sector
Prescribing 
pharmacists
Non-
prescribing 
pharmacists
Pharmacy 
technician Total
Primary care 2 13  15
Community 1 9 1 11
Portfolioa  1 —  1
Total 4 22 1 27
aEmployed in a split role across primary care and community pharmacy. 
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All stakeholders prioritised regular, responsive medication reviews 
by PIPs as a way to address gaps in managing chronic disease and en-
hancing the safety of residents living with comorbidities. GPs’ onerous 
workload limited their capacity for “time-consuming” procedures and 
“complexities” in reviewing and managing medication to “keep it right for 
this population” (GP8-FG). Pharmacists acknowledged these limitations: 
they saw medicines dealt with as “an after-thought” by time-pressed 
doctors, whose care-home visits were absorbed in treating acute prob-
lems, and argued that PIPs could do “more proactive work” (P10-FG). 
For one GP, a PIP who helped “tie up all those loose ends” to ensure 
residents received appropriate medication and who liaised with GPs and 
community pharmacies “would be the answer to my prayers” (GP1-FG).
GPs admitted that they found it “difficult managing all the com-
plexity and the co-morbidity” (GP6-FG) and that “GPs don't under-
stand” how care homes obtain and administer medicines (GP7-FG). 
Care-home systems incompatible with medicines supply were re-
ported as impairing timely ordering and medicines supply. If a PIP 
oversaw and bridged gaps in these processes, the “mayhem” be-
tween care homes, pharmacies and GP practices, typified by “huge 
amount of telephone contact …with the [GP’s] receptionist over pre-
scribing issues”, could be eliminated (GP7-FG).
While no system appeared to ensure efficacy and efficiency in 
care-home prescribing, a PIP model was seen to offer a means to ad-
dress this—but only if well-informed about older people's medicine 
and care homes.
3.1.2 | Knowledge of older people's medicine and 
care homes
Knowledge of older people's conditions and an appreciation of 
what it means to live in a care home were considered essential 
for the PIP. It was seen as vital that the PIP take into account 
the whole person, not the specific condition, recognise how care 
homes operate and understand practices and cultures within care 
homes.
Several GPs and pharmacists recommended PIPs be trained in 
geriatric medicine. One GP cautioned that pharmacists with little 
experience of older people might treat the condition as a “single sys-
tem” (GP3-I) rather than seeing the nuanced picture of older peo-
ple's lives. Others recommended that PIPs learn about the impact of 
changing or starting medication on the overall health and quality of 
life of frail older people.
Pharmacists remarked that colleagues who were otherwise highly 
skilled might lack direct experience of care homes or be unaware of 
their protocols and regulatory frameworks. GPs, pharmacists and 
care-home managers felt that PIPs must become conversant with 
mandatory guidelines and regulations governing medications in care 
homes. Knowledge of care-homes’ organisational and cultural prac-
tices was also deemed necessary, one manager arguing that PIPs must 
“understand how care homes actually really function” (CHM4-FG).
Stakeholders prioritised well-developed communication skills to 
interact and share knowledge with residents, “particularly [those] 
with cognitive impairment” (P1-FG). These skills included perceiv-
ing the whole person during medication reviews, such as noticing a 
resident's “hearing aid over on a table that they can't reach” (P5-FG). 
One care-home manager imagined a PIP initiating “a little chat” as a 
medications expert with residents (CHM2-FG). For another manager, 
a PIP’s capacity to talk “with … not down to” residents was as import-
ant as pharmacological expertise (CHM3-FG). GPs and pharmacists 
recommended that a PIP be sensitive to residents’ vulnerabilities 
regarding medications. This surfaced separately when a resident re-
ported feeling “nervous” when “the appearance of a tablet changes”; 
she suggested a PIP could answer residents’ uncertainties about 
such changes (RR3-FG).
3.2 | Implementation barriers and facilitators
While stakeholders broadly accepted the proposed service, they 
questioned the PIP’s specific responsibilities and queried how the 
role would be understood and incorporated into the care-home en-
vironment. Two implementation issues—clarity of the PIP’s role and 
responsibilities and integrated team-working with the PIP—were 
seen to reflect the need to achieve effective multi-professional 
team-working.
3.2.1 | Clarity of PIP role and responsibilities
Stakeholders advocated clarity about the PIP role. Because GPs 
hold ultimate responsibility for patients’ healthcare, doctors ar-
gued that information be shared and monitored with the PIP, based 
upon effective, regular communication between them. Priorities for 
ensuring clarity were eliminating duplicate orders and preventing 
omissions in carrying out medication responsibilities. For care-home 
staff, residents and relatives, a concrete and shared understanding 
of the PIP’s role would help to improve communication for the ben-
efit of medicines management and residents themselves.
Stakeholders emphasised the need to understand each other's 
systems to increase the acceptability and viability of the PIP service. 
To promote such understanding, they recommended attaching PIPs 
to GP practices, thereby allowing PIPs to function successfully and 
benefit both care homes and GPs.
Care-home managers raised potential barriers to the service 
from needing to respect residents’ traditional preference to discuss 
medical issues with their GP to providing extra training for care-
home staff about the new PIP role. The need to carefully consider 
residents’ and staff concerns was echoed by pharmacists and GPs. 
One GP believed that residents should be reassured that the PIP 
interacting with them had “one hand in the practice” (GP10-FG). A 
pharmacist foresaw initial “apprehension” if all parties did not un-
derstand each other's roles or see benefits for residents (P9-FG). As 
if exemplifying this point, a care-home staff member initially que-
ried why PIPs needed access to residents’ care records; on hearing 
fuller details about the PIP role, he revised his view of such access 
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for supporting residents, with a colleague in his focus group adding, 
“all the medications will be reviewed … I think that would be nice” 
(CHS1-FG). Such expressed doubts underlined that clear communi-
cation would be essential for maximising stakeholder understanding 
and acceptance of the role's remit.
A relative stressed their need to be kept aware of the new ser-
vice “because often the residents can't pass on the information that 
the relatives would like to know” (RR2-FG). Another relative saw a 
PIP meeting the significant need of transferring information from 
GPs to residents and of answering relatives’ questions more speedily 
than time-pressed doctors, so that “everybody that needs to know 
is informed” (RR1-FG).
Although no GP believed that the PIP’s role should include diag-
nosis, no GPs attached risk to a PIP monitoring and reviewing med-
icines or attending to time-intensive matters such as synchronising 
residents’ prescriptions. GPs expressed confidence in pharmacists’ 
skills and applying these within the intervention, “looking at interac-
tions and side-effects” (GP3-I) and bringing expertise “to guide us to 
things that we might have missed” (GP12-FG).
Pharmacists unequivocally shared GPs’ reservations about diag-
nosing and endorsed the need for role clarity, including boundaries 
on expectations of the PIP’s tasks. One pharmacist acknowledged 
that “an ‘everything has to be done by a GP’-culture” (P2-I) among 
some care-home staff could be changed through good models of 
working and clear role definitions. As one GP advised, “it's about 
framing your service so that actually people understand what bene-
fit it's going to be for them” (GP13-I). Stakeholders’ emphasis on role 
clarity and appropriate communication is further examined within 
the second implementation challenge: integrated team-working.
3.2.2 | Integrated social and professional team-
working
Stakeholders believed that to embed the new service the PIP must 
establish communicative relationships with GP practices and care 
homes, from which shared understanding of roles, working co-op-
eratively rather than independently, developing trust and providing 
continuity of service could result. This would take time and depend 
on the PIP acquiring relevant experience and knowledge of the con-
text of older residents’ health.
Many participants reflected on their positive experience of 
multi-professional working when debating the benefits of integrat-
ing a PIP into a team; one cited an “effective working relationship” 
between GPs and pharmacists (GP6-FG) and another valued phar-
macists being linked to GP practices because “they're accountable 
to the GP” (P5-FG). One GP urged PIPs be practice-based because 
“nuances with managing the elderly [require] co-operative working” 
(GP14-FG) while another cautioned that a PIP acting independently 
of professionals involved with residents’ care risked being a “recipe 
for disaster for … looking after patients” (GP7-FG).
Some GPs and care-home managers conjectured that PIPs might 
educate care-home staff to raise their awareness of medications. 
One doctor believed that this could “improve patients’ experience 
with tablets” (GP2-FG). This resonated with residents’ desire to 
know about their medications:
…nobody [is there] to ask things about your medication, 
as the person giving you the drugs doesn’t have much 
knowledge, so they can’t explain (RR4-FG)
Pharmacists also envisaged benefits for staff and residents if a 
PIP were an in-house resource on medications. They suggested that a 
sensitive approach would increase the likelihood of collegial working if 
staff saw the PIP as part of a “care package” team for residents, rather 
than someone who might be “checking up on [staff]” (P6-FG).
Stakeholders’ emphasis on clarity in the PIP role reinforced 
their need to establish whether and how this new role would add 
a distinctive and necessary new element to their multi-professional 
working environment. Clearly defined team-working for the benefit 
of residents would increase the new service's acceptability. Their at-
tention to team-working suggested specific ways that distinctive PIP 
contributions could be integrated to strengthen, not complicate, the 
complex collaborations on which care homes depend.
4  | DISCUSSION
Our study explored stakeholders’ expectations of a feasible PIP ser-
vice, the key components they specified for the role, the context of 
professional and multidisciplinary practices relating to care homes 
for the proposed service and the barriers and facilitators affecting 
its acceptability. Our TDF-informed approach then enabled us to 
identify what components stakeholders deemed key and what con-
textual practices they saw as relevant to mitigate implementation 
barriers and to promote PIP feasibility and acceptability. This recog-
nised the complexity of care-home environments, with their many 
different players, organisational processes and systems and varia-
tions in resources providing care to frail older people.
Our comparative analysis revealed no specific inter-country dif-
ferences across the study sites. Stakeholders welcomed this novel 
role on many fronts, beginning with their expectation that the PIP 
would help to address chronic disease management challenges, in 
which medication reviews were made complex and time-consuming 
by residents’ multiple co-morbidities which complicated pharmaco-
logical interactions and side-effects. GPs and most pharmacists em-
phasised needing to understand the complexities in managing the 
health of older care-home residents and the impact of frailty and 
advancing age on their responses to drugs. Introducing a prescribing 
pharmacist in care homes was seen to offer specific potential bene-
fits to residents, care homes and GPs.
Stakeholders believed that acceptability of the service would in-
crease if the PIP offered the means to strengthen mechanisms to 
ensure efficient, effective prescribing in care homes. Repeated prob-
lems stemmed from no individual overseeing medication needs out-
side scheduled medicines management reviews. GPs and care-home 
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managers were left with the task of repairing treatment discontinu-
ities when professional and organisational procedures contradicted 
each other and, echoing previous research, identified the absence of 
a “whole team” approach, no one with overall responsibility for med-
icines management and a lack of coordination (Barber et al., 2009).
Of primary importance to GPs was that a PIP initiative giving 
scope to the PIP to conduct medication reviews would save GPs time 
and work most largely given to solving acute problems when visit-
ing care homes. They would not support the innovation if it would 
likely make their already burdensome workload more complex, as re-
ported elsewhere for other well-intended changes (Scott, Mannion, 
Davies, & Marshall, 2003). Potential benefits GPs identified were 
having better access to up-to-date knowledge on medication inter-
actions and pharmaceutical guidelines. Although building multi-pro-
fessional relationships through the proposed PIP service would take 
time, GPs and pharmacists also saw these relationships as enhancing 
communication and trust around medications issues. Indeed, GPs 
predicated their welcome of the PIP initiative on establishing a trust-
based relationship which ensured mutually-recognised remits and 
competencies (RPS, 2016).
We obtained comprehensive understanding from stakehold-
ers of processes necessary to inform the intervention in order to 
maximise its chance of achieving a meaningful impact in practice 
(Davidoff, Dixon-Woods, Leviton, & Michie, 2015). Central to the 
acceptability and viability of introducing a PIP was that everyone 
involved in implementing it “understand each other's systems”. This 
included recognising established organisational and cultural prac-
tices in care homes and primary care during implementation and 
ensuring good communication around related changes. A review 
of nursing-home culture identified similar needs raised by intro-
ducing change within complex settings (Shier, Khodyakov, Cohen, 
Zimmerman, & Saliba, 2014). In this study, stakeholders’ knowledge 
of context and procedures revealed key ingredients to increase the 
viability of the PIP: both pharmacists and doctors argued that a PIP 
working in isolation from the GP practice or other health profes-
sionals in care homes might be a “disaster” for residents’ care. By 
contrast, they envisaged positive outcomes for a PIP embedded in 
collegial, communicative working with GP practices.
Both shared and distinct emphases surfaced across stake-
holder groups. For example, all groups mentioned constraints on 
time-pressed GPs in providing continuity of care for residents and 
so supported introducing a prescribing pharmacist to take overall 
responsibility for medicines management. Beliefs about a PIP’s ca-
pabilities and role were, however, expressed in different ways. Care-
home managers stressed the potential advantages of a PIP spending 
time with residents to explain medications, projecting both expert 
and social roles in the service, while residents and relatives saw in 
it a needed, helpful channel of timely communication and reassur-
ance about medications. Such views reflect findings that care-home 
residents are more satisfied when they are involved as full partners 
in their care and that healthcare support should reflect residents’ 
own perspectives (My Home Life, 2007; Social Care Institute for 
Excellence, 2013).
Integrated team-working was another key component: stake-
holders were likelier to consider the PIP role acceptable and viable 
if effective team-working were embedded in its implementation, 
echoing research on healthcare change (Scott et al., 2003). Team-
working took several forms: care-home managers observed that 
their staff could learn more about medication management from a 
PIP, care-home staff expected a PIP could answer their questions 
about medicines while residents and relatives saw the PIP providing 
a reassuring sense of safety in medications. GPs strongly preferred 
that PIPs be integrated into their practice teams and acquire appro-
priate knowledge of older people's medicine to enable them to see 
residents holistically, not as detached systems. Pharmacists echoed 
these preferences, adding that PIPs could relieve some of the 
time-pressures on GPs. Their views feed into the growing evidence 
that an extended role for pharmacists in care homes should help to 
reduce the burden placed on doctors (Chaplin, 2016), which in turn 
reflects the increasing variation in the UK’s primary-care workforce. 
The widespread inter-professional engagement with this research 
indicates the range of potential interest in the PIP role across the 
whole workforce.
A clearly defined PIP role was considered crucial. Residents 
and relatives made their likely acceptance of the new service con-
ditional on having its purpose and elements carefully explained 
to them. These outcomes resonate with UK quality standards on 
involving families and carers in decisions about treatment and 
care in managing medicines in care homes (NICE, 2015). Explicit 
agreement on areas where PIPs might prescribe was essential for 
GPs and pharmacists. All participants emphasised that compo-
nents of the PIP role be discernible at the micro-level of individ-
ual actions, especially as experienced by residents and staff, and 
incorporated at the macro-level of care home and GP practice 
organisation.
Although our findings are presented separately in contex-
tual and implementation categories, these cannot be dissociated 
from each other in practice. Contextual factors framed how 
stakeholders envisaged implementation issues as making either 
more or less feasible the introduction of a PIP. For example, 
effective team-working with the PIP, in GP practices and care 
homes (an implementation concern), depended in part upon the 
PIP acquiring appropriate knowledge of older people's medicine 
(a contextual issue). GPs saw working relationships as ideal if 
PIPs were practice-based (implementation) and if chronic dis-
eases were to be most successfully managed to benefit residents 
(contextual). Guidelines and existing research underscore that 
specifically addressing both context and implementation bar-
riers is most likely to guarantee improved outcomes for older 
people in residential settings (Chaplin, 2016; NICE, 2015; RPS, 
2016). As indicated above, stakeholders’ awareness of residents’ 
frailties regarding medication suggested that GPs, pharma-
cists, care-home staff and relatives widely agreed on what spe-
cific knowledge, skills and environmental factors were critical 
to shaping the successful introduction and implementation of 
the PIP service. Linking multiple stakeholder views envisioning 
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a proposed PIP innovation was the common belief that its ac-
ceptability and viability would depend on all stakeholders un-
derstanding each other's systems.
4.1 | Limitations and strengths of this study
A limitation may have been the minimal representation of residents 
and relatives in intervention-development workshops, perhaps be-
cause these were held on university premises outside their usual 
residence. There may have been bias in that participants were self-
selected and therefore perhaps had favourable expectations of the 
PIP role and may not have captured the views of individuals more 
likely to resist the innovation.
A particular strength was the independence of the qualitative 
researchers with no professional or clinical interest in this specific 
area of practice. Using the TDF to inform the approach for framing 
topics discussed with stakeholders strengthened the study by sen-
sitising us to implementation issues relevant in the context of this 
proposed innovation. TDF use also facilitated stakeholders to reveal 
contextual and implementation barriers to defining, deploying and 
integrating a PIP role within existing services. It also drew compre-
hensively upon stakeholders’ experiences and awareness of context, 
social and pharmaceutical relationships.
5  | CONCLUSIONS
For a new pharmaceutical care service to be effectively embedded, 
stakeholders’ views highlighted that securing the acceptability and 
viability of the PIP role would mean taking steps to ensure that all 
those involved in delivering and using it could “understand each oth-
er's systems”. Enabling such mutual understanding would address 
contextual and implementation barriers and be relevant to identify-
ing feasible practices for addressing residents’ medications-related 
safety and experience of medications. Current UK strategy aims to 
enhance care in care-home settings partially through prescribing 
pharmacists. This paper demonstrates the widespread articulation 
by professional and lay stakeholders of the need for these pharma-
cists to take time to understand care-home-related systems they will 
operate within, before trying to enhance resident safety in better 
managing their medicines.
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